Comparison of Oral Allopurinol with Intralesional Meglumine Antimoniate in Treatment of Cutaneous Leishmaniasis

Memoona Nadeem; Nadia  Iftikhar; Tehseen  Naveed

doi:10.51253/pafmj.v76i5.13387

Authors

Memoona Nadeem Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Nadia Iftikhar Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Tehseen Naveed Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i5.13387

Keywords:

Allopurinol, Cutaneous Leishmaniasis, Drug, Intralesional, Meglumine Antimoniate, Treatment

Abstract

Objective: To establish efficacy of Allopurinol in Cutaneous Leishmaniasis.

Study Design: Quasi experimental study.

Place and Duration of study: Department of Dermatology, Combined Military Hospital, Rawalpindi Pakistan, from Apr to Sep 2024.

Methodology: After approval from hospital ethical committee 60 patients of age ranging from 20 – 50 years, who fulfilled the inclusion criteria were enrolled in this study. Duration of study was 6 months. Patients were randomly allocated to Group-1 and Group-2 and each group had 30 participants. Group-1 patients were given oral Allopurinol 10-15mg/kg in 2-3 divided doses for 8 weeks. Group-2 patients were given 1-2ml intralesional Meglumine Antimoniate according to lesion size for 8 weeks. Lesions were assessed at the end of treatment by palpation to measure the induration and by ruler to measure the size of lesion. The drug was considered efficacious if there was 75 percent reduction in size and induration of lesion.

Results: At the end of eight weeks, complete response (effectiveness) was observed in 22(73.3%) patients in Group-1 and 27(90%) patients in Group-2. When compared these results were found to be statistically significant with a p-value of 0.032.

Conclusion: Intralesional Meglumine Antimoniate is more effective than oral Allopurinol in the treatment of Cutaneous Leishmaniasis.

Downloads

Download data is not yet available.

References

1. Moein D, Masood D, Saeed M, Abbas M. Epidemiological aspects of cutaneous leishmaniasis during 2009-2016 in Kashan city, Iran. Korean J Parasitol 2018; 56(1): 21-24.

https://doi.org/10.3347/kjp.2018.56.1.21

2. Ayaz MM, Nazir MM, Najeebullah, Zaman A, Akbar A, Zeeshan M, et al. Cutaneous leishmaniasis in Multan, Pakistan: a neglected disease. J Med Entomol 2018; 55(4): 1040-1044.

https://doi.org/10.1093/jme/tjy003

3. Riebenbauer K, Czerny S. The changing epidemiology of human leishmaniasis in the non-endemic country of Austria between 2000 to 2021, including a congenital case. PLoS Negl Trop Dis 2024; 18(1): e0011875.

https://doi.org/10.1371/journal.pntd.0011875

4. Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis 2016; 3(3-4): 98–109.

https://doi.org/10.1177/2049936116646063

5. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 2017; 96(1): 24-45.

https://doi.org/10.4269/ajtmh.16-84256

6. Garza-Tovar TF , Sacriste-Hernández MI , Juárez-Durán ER, R Arenas R. An overview of the treatment of cutaneous leishmaniasis. Fac Rev 2020; 9: 28.

https://doi.org/10.12703/r/9-28

7. Muhammad N, Sagheer F, Majid M. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis. J Ayub Med Coll Abbottabad 2022; 34(4): 849-853.

https://jamc.ayubmed.edu.pk/index.php/jamc/article/view/11135

8. Castro MdM, Rode J, Machado PRL, Llanos-Cuentas A, Hueb M, Cota G, et al. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study. PLoS Negl Trop Dis 2023; 17(1): e0011029.

https://doi.org/10.1371/journal.pntd.0011029

9. Mounia A, Mohamed E, Mohamed H, Samia B. A Community Based Survey of Knowledge, Attitudes, and Practices Concerning Leishmaniasis in Central Morocco. J Community Health 2022; 47(6): 932-942.

https://doi.org/10.1007/s10900-022-01126-z

10. Uliana SRB, Trinconi CT, Coelho AC. Chemotherapy of leishmaniasis: present challenges. Parasitology 2018; 145(4): 464-480. https://doi.org/10.1017/S0031182016002523

11. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326(11): 741-744.

https://doi.org/10.1056/nejm199203123261105

12. De Vries H.J.C, Schallig H.D. Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments. Am J Clin Dermatol 2022; 23: 823–840.

https://doi.org/10.1007/s40257-022-00726-8

13. Moncada-Diaz M.J, Rodríguez-Almonacid C.C, Quiceno-Giraldo E, Khuong F.T.H, Muskus C, Karamysheva Z.N. Molecular Mechanisms of Drug Resistance in Leishmania spp. Pathogens 2024; 13(10): 835.

https://doi.org/10.3390/pathogens13100835

14. Zabolinejad, N., Layegh, P., Abbasi Shaye, Z., Salehi, M., Ghanizadeh, S. Evaluating the effect of oral clarithromycin on acute cutaneous leishmaniasis lesions compared with systemic glucantime. J Dermatol Treat 2023; 33(3): 1418–1423.

https://doi.org/10.1080/09546634.2020.1825612

15. Arboleda M, Barrantes S, Úsuga LY Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series Rev Soc Bras Med Trop 2019; 52: e20180211. https://doi.org/10.1590/0037-8682-0211-2018

16. Aronson N, Joya CA. Cutaneous leishmaniasis: an update. Infect Dis Clin North Am 2019; 33(1): 101-117.

https://doi.org/10.1016/j.idc.2018.10.004.

17. Rojas CE, Verduguez OA, Tordoya-Titichoca. Intralesional meglumine antimoniate: safe therapy for cutaneous leishmaniasis. Trop Med Infect Dis 2022; 7(10): 286.

https://doi.org/10.3390/tropicalmed7100286

18. Henten S, Bialfew F, Hassen S. Clinical outcomes in cutaneous leishmaniasis treated with SSG and allopurinol. Trop Med Infect Dis 2023; 8(8): 414.

https://doi.org/10.3390/tropicalmed8080414

19. Rashid ur H, Ullah I, Adeeb HS. Combined oral allopurinol and intralesional sodium stibogluconate in cutaneous leishmaniasis. J Ayub Med Coll Abbottabad 2020; 32(4): 558-561.

https://www.jamc.ayubmed.edu.pk/index.php/jamc/article/

20. Vahid MG, Zahra D, Emadodin D. Treatment of cutaneous leishmaniasis with allopurinol plus itraconazole. Am J Trop Med Hyg 2023; 108(6): 11646. https://doi.org/10.4269/ajtmh.22-0733